Sridama V, McCormick M, Kaplan E L, Fauchet R, DeGroot L J
N Engl J Med. 1984 Aug 16;311(7):426-32. doi: 10.1056/NEJM198408163110702.
We treated 187 patients who had Graves' disease with low-dose radioactive iodide (131I), using a protocol that included a compensation for thyroid size. The incidence of early hypothyroidism (12 per cent) was acceptably low in the first year after 131I treatment, but we found a cumulative high incidence (up to 76 per cent) at the end of the 11th year. In contrast, the incidence of permanent hypothyroidism was relatively stable in 166 surgically treated patients, increasing from 19 to 27 per cent at the end of 11 years. Among 122 medically treated patients, only 40 per cent entered remission, and hypothyroidism developed in 2 per cent during the same period of follow-up. The long-term incidence of hypothyroidism in our patients treated with low-dose 131I therapy was much higher than that found in earlier studies using a comparable dose. Our study suggests that it will be difficult to modify therapy with 131I alone to produce both early control of thyrotoxicosis and a low incidence of hypothyroidism.
我们采用一种包含甲状腺大小补偿的方案,用低剂量放射性碘(¹³¹I)治疗了187例格雷夫斯病患者。¹³¹I治疗后第一年,早期甲状腺功能减退的发生率(12%)较低,尚属可接受范围,但我们发现在第11年末累积发生率较高(高达76%)。相比之下,166例接受手术治疗的患者中,永久性甲状腺功能减退的发生率相对稳定,11年末从19%增至27%。在122例接受药物治疗的患者中,只有40%进入缓解期,且在相同随访期内有2%发生甲状腺功能减退。我们采用低剂量¹³¹I治疗的患者中,甲状腺功能减退的长期发生率远高于早期使用类似剂量的研究。我们的研究表明,仅用¹³¹I调整治疗方案,很难在早期控制甲状腺毒症的同时降低甲状腺功能减退的发生率。